Even though no significant risk association for MTC development was identified, perhaps due to the small sample size, extrathyroidal tumor extension was significantly less in patients with the CDKN1A SNP as compared to those with wild type CDKN1A (50% versus 92%, P = .037). Here, CDKN1A is linked to neoplasm.